L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO

PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI

Translated title of the contribution: Renin inhibitor remikiren (RO 42-5892) in hypertensive patients on chronic diuretic treatment: The endocrine profile and hemodynamic effects

G. Villa, L. Picardi, I. Kobrin, M. Piatti, R. Saponaro, A. Salvadeo

Research output: Contribution to journalArticle

Abstract

Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.

Original languageItalian
Pages (from-to)43-51
Number of pages9
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume12
Issue number1
Publication statusPublished - 1995

Fingerprint

Diuretics
Renin
Hemodynamics
Blood Pressure
Hydrochlorothiazide
Therapeutics
Random Allocation
Placebos
remikiren
Kidney
insulin receptor-related receptor

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{d4cdbdca34544708b1c850b0b7496495,
title = "L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO: PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI",
abstract = "Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.",
keywords = "hypertension, Remikiren, renal hemodynamics, renin-inhibitor",
author = "G. Villa and L. Picardi and I. Kobrin and M. Piatti and R. Saponaro and A. Salvadeo",
year = "1995",
language = "Italian",
volume = "12",
pages = "43--51",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",
number = "1",

}

TY - JOUR

T1 - L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO

T2 - PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI

AU - Villa, G.

AU - Picardi, L.

AU - Kobrin, I.

AU - Piatti, M.

AU - Saponaro, R.

AU - Salvadeo, A.

PY - 1995

Y1 - 1995

N2 - Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.

AB - Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.

KW - hypertension

KW - Remikiren

KW - renal hemodynamics

KW - renin-inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0028847901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028847901&partnerID=8YFLogxK

M3 - Articolo

VL - 12

SP - 43

EP - 51

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 1

ER -